Turn to the nation's most objective and informative daily environmental news resource to learn how the United States and key players around the world are responding to the environmental...
By Michael Kepp
Feb. 18 — Brazil is poised to make it easier for companies to conduct bioprospecting and sign benefit-sharing contracts for extracting and commercializing products derived from genetic resources.
Perhaps the year's most important piece of environmental legislation in Brazil, the bill is aimed primarily at companies developing new pharmaceuticals or cosmetics made with genetic resources, materials from local plants, animals and micro-organisms.
“The bill will greatly reduce the red tape in bioprospecting and the commercialization of products derived from genetic resources,” Adriana Diaferia, vice president of Grupo FarmaBrasil, an association of local pharmaceutical companies, told Bloomberg BNA Feb. 11. “And it will provide greater juridical security than the confusing 2001 presidential measure that it replaces.”
The bill was approved by the lower house of Congress, the Chamber of Deputies, Feb. 10. The Senate is expected to approve the measure (PL 7,735/2014) in March, and then it is expected to be sanctioned by the president and become law.
Under the measure, companies and research institutes doing bioprospecting for research or product development would be required merely to electronically register such activities with the Genetic Assets Management Council (CGEN), an interministerial regulatory body.
Since 2001, researchers and companies have needed explicit approval from CGEN before they could undertake any search for new products from nature, a requirement that has slowed bioprospecting considerably.
Under the new bill, only when a company is ready to commercialize a product derived from that bioprospecting would it have to sign a CGEN-approved benefit sharing contract.
The bill would set a flat payment of 1 percent of the annual net revenues of the commercialized product, a fee that the company would deposit into a special fund. The government would distribute some of those proceeds to the local providers of the genetic resources.
In addition, the bill would allow agreements with the government for specific genetic assets that would reduce the percentage of annual net sales in any benefit-sharing agreement to a minimum of 0.1 percent.
Currently, companies and providers of genetic resources are free to negotiate the percentage of annual net sales that providers receive, although most receive less than 1 percent.
Some environmental groups object to the measure's language restricting benefit-sharing to genetic resources that are “the main value-added [biological] materials” in commercialized products.
“The bill benefits pharmaceutical and cosmetics companies by making it easier for them to bioprosect here and to commercialize products derived from genetic resources,” Maurício Guetta, a lawyer with nongovernmental organization Social Environmental Institute, told Bloomberg BNA Feb. 11. “But its benefit-sharing restrictions will reduce the amount of benefit-sharing money going into the government fund, part of which will be passed on to providers of those genetic resources, likely reducing their proceeds.”
Another provision would require companies that commercially develop genetically improved or genetically modified “native” seeds to sign benefit-sharing contracts with the government or with the traditional farmers who help develop and improve them.
To contact the reporter on this story: Michael Kepp in Rio de Janeiro at email@example.com
To contact the editor responsible for this story: Greg Henderson at firstname.lastname@example.org
The Chamber of Deputies bill (No. 7,735/2014) is available, in Portuguese, at http://bit.ly/16Xw3bs.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)